Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share

The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty.

See why the elites are pouring billions into gold.

James S. J. Manuso net worth and biography

James Manuso Biography and Net Worth

Director of Ocuphire Pharma

James S. Manuso, Ph.D., M.B.A., Chairman and CEO of Talfinium Investments, Inc., has served on the Ocuphire Board since January 2019. Dr. Manuso is an international biotechnology/pharmaceutical industry CEO and management consultant with over 25 years’ experience. He has co-founded multiple biotech companies where he held C-level management positions. As chairman and CEO of Astex Pharmaceuticals, Inc., Dr. Manuso led the sale of the Company to Otsuka Pharmaceuticals for $886 million. A former Board Member of the Biotechnology Industry Association, he has served on the boards of several private and public companies in the US, UK, France, Canada and Ireland. Dr. Manuso earned a B.A. with honors in Economics and Chemistry from New York University, a Ph.D. in Experimental Psychology and Genetics from the New School University, and an Executive M.B.A. from Columbia Business School.

What is James S. J. Manuso's net worth?: The estimated net worth of James S. J. Manuso is at least $34,727.70 as of May 20th, 2022. Dr. Manuso owns 21,570 shares of Ocuphire Pharma stock worth more than $34,728 as of April 28th. This net worth evaluation does not reflect any other investments that Dr. Manuso may own. Learn More about James S. J. Manuso's net worth.
How do I contact James S. J. Manuso?: The corporate mailing address for Dr. Manuso and other Ocuphire Pharma executives is 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD, 20850. Ocuphire Pharma can also be reached via phone at (248) 681-9815 and via email at [email protected]. Learn More on James S. J. Manuso's contact information.
Has James S. J. Manuso been buying or selling shares of Ocuphire Pharma?: James S. J. Manuso has not been actively trading shares of Ocuphire Pharma over the course of the past ninety days. Most recently, on Friday, May 20th, James S. J. Manuso bought 5,000 shares of Ocuphire Pharma stock. The stock was acquired at an average cost of $1.99 per share, with a total value of $9,950.00. Following the completion of the transaction, the director now directly owns 21,570 shares of the company's stock, valued at $42,924.30. Learn More on James S. J. Manuso's trading history.
Who are Ocuphire Pharma's active insiders?: Ocuphire Pharma's insider roster includes James Manuso (Director), and Jay Pepose (Director). Learn More on Ocuphire Pharma's active insiders.
Are insiders buying or selling shares of Ocuphire Pharma?: During the last twelve months, Ocuphire Pharma insiders bought shares 3 times. They purchased a total of 37,000 shares worth more than $74,100.00. The most recent insider tranaction occured on March, 21st when COO Joseph K Schachle bought 2,000 shares worth more than $4,100.00. Insiders at Ocuphire Pharma own 8.7% of the company. Learn More about insider trades at Ocuphire Pharma.
Information on this page was last updated on 3/21/2024.

James S. J. Manuso Insider Trading History at Ocuphire Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/20/2022	Buy	5,000	$1.99	$9,950.00	21,570
11/18/2021	Buy	2,000	$3.50	$7,000.00

James S. J. Manuso Buying and Selling Activity at Ocuphire Pharma

Ocuphire Pharma Company Overview

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.

Today's Range

Now: $1.61

$1.55

$1.63

50 Day Range

MA: $2.06

$1.51

$2.64

2 Week Range

Now: $1.61

$1.50

$6.60

Volume

113,959 shs

Average Volume

268,951 shs

Market Capitalization

$39.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.33